reports
- Dr Jonas Peciulis
A leading remote cardiac monitoring player
LifeWatch specialises in ECG-based remote cardiac monitoring services and is one of the leading companies in this space in the US, with around four million patients monitored to date. The company had a solid FY15, with 8.3% adjusted revenue growth and its strongest EBITDA in six years. However, 2016 was turbulent, mainly as a result of costly but one-off legal settlements. Having streamlined its cost base and left the legacy issues behind it, LifeWatch is now well placed to capitalise on healthy...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Insider bought: A director bought 10,000 shares at 9.295CHF and
A director at LifeWatch AG bought 10,000 shares at 9.295CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
QuickView: Maintaining the rhythm
A strategic partnership with AliveCor and US (FDA 510k) and EU (CE mark) approvals for the mobile cardiac telemetry (MCT) patch kicks off an important year for LifeWatch. With a full turnaround of the company’s fortunes nearly complete, there is a renewed focus on growth via organic and external means. The recent purchase of FlexLife Health and suspension of its home sleep testing services are testament to LifeWatch’s new strategic direction.
QuickView: Established and growing digital health player
LifeWatch’s remote diagnostic monitoring services provide physicians with critical information to determine appropriate treatment and thereby improve patient outcomes. Digital health is a rapidly advancing sector that is playing an ever important role in the trend towards a more holistic approach to diagnosing, treating and monitoring diseases. LifeWatch specialises in ECG-based cardiac monitoring devices and systems. H115 revenues rose 9.1% to $52.5m, driven by growth in the US market, and th...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.